Pharmacodynamic and clinical efficacy of reduced ticagrelor maintenance doses in patients with coronary artery disease.

CONCLUSIONS: Ticagrelor doses below 90 mg BID generally show acceptable profile of platelet inhibition. Number of studies reporting clinical outcomes in CAD patients receiving reduced MD of ticagrelor are limited, however available results indicate that in stable setting this strategy offers improved safety with preserved efficacy in prevention of thrombotic events. PMID: 33211543 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research